Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Melanoma Development Depends on the Activity of the RUNX2 Transcription Factor

By BiotechDaily International staff writers
Posted on 28 Apr 2014
Print article
Image: Expression of RUNX2 in the nucleus of 1205LU melanoma cells (Photo courtesy of the Rutgers Cancer Institute).
Image: Expression of RUNX2 in the nucleus of 1205LU melanoma cells (Photo courtesy of the Rutgers Cancer Institute).
The transcription factor RUNX2 (runt-related transcription factor 2) has been found to play a critical role in melanomagenesis, the processes leading to development of the skin cancer, melanoma.

The RUNX2 gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with a Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression.

Investigators at the Rutgers Cancer Institute (New Brunswick, NJ, USA) examined the role of the RUNX2 transcription factor in melanomagenesis. They reported in the March 31, 2014, online edition of the journal Cancer Letters that the expression of transcriptionally active RUNX2 was increased in melanoma cell lines as compared with normal human melanocytes. Using a melanoma tissue microarray, they showed that RUNX2 levels were higher in melanoma cells as compared with nevic melanocytes.

Genetic silencing of RUNX2 in melanoma cell lines significantly decreased Focal Adhesion Kinase expression and inhibited cell growth, migration, and invasion ability. Furthermore, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration.

“Successful efforts to render transcription factors “drugable” by interfering with different aspects of their transcriptional activity make this class of proteins attractive targets for therapy,” said senior author Dr. Karine Cohen-Solal, assistant professor of medicine at the Rutgers Cancer Institute. “Exploring the role of RUNX2 in the development of melanoma is likely to reveal new mechanisms driving melanoma progression and identify a target for novel antimelanoma agents, thereby opening new avenues for the treatment of this disease.”

Related Links:
Rutgers Cancer Institute



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.